Management of liver transplant recipients with recurrent hepatitis C

Current Opinion in Organ Transplantation

Volumn 14, Issue 3, 2009, Pages 221-224

  McCashland, Timothy M ^a  

^a UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

Author keywords

Hepatitis C; Histology; Immunosuppression; Liver transplantation

Indexed keywords

ANTIVIRUS AGENT; CALCINEURIN INHIBITOR; CYCLOSPORIN; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; STEROID; TACROLIMUS; VIRUS RNA; IMMUNOSUPPRESSIVE AGENT;

DIABETES MELLITUS; DRUG DOSE REDUCTION; GRAFT RECIPIENT; GRAFT REJECTION; HEPATITIS C; HISTOPATHOLOGY; HUMAN; IMMUNE RESPONSE; IMMUNOHISTOCHEMISTRY; IMMUNOSUPPRESSIVE TREATMENT; LIVER CIRRHOSIS; LIVER FIBROSIS; LIVER GRAFT REJECTION; LIVER TRANSPLANTATION; METABOLIC SYNDROME X; PLASMAPHERESIS; PORTAL VEIN; RECURRENT INFECTION; REVIEW; SURVIVAL RATE; TREATMENT OUTCOME; GRAFT SURVIVAL; MORTALITY; RECURRENT DISEASE;

ANTIVIRAL AGENTS; DIABETES MELLITUS; GRAFT SURVIVAL; HEPATITIS C; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LIVER TRANSPLANTATION; METABOLIC SYNDROME X; RECURRENCE; TREATMENT OUTCOME;

EID: 67651050045     PISSN: 10872418     EISSN: 15317013     Source Type: Journal    
DOI: 10.1097/MOT.0b013e32832ade76     Document Type: Review

References (32)

1. Forman LM, Lewis JD, Berlin JA, et al. The association between hepatitis C infection and survival after orthotopic liver transplantation. Gastroenterology 2002; 122:889-896. (Pubitemid 34267271)
2. Mukerjee S, Sorrell MF. Controversies in liver transplantation for hepatitis C. Gastroenterology 2008; 134:1777-1788.
3. Verna EC, Brown RS. Hepatitis Candliver transplantation: enhancing outcomes and should patients be retransplanted. Clin Liver Dis 2008; 12:637-659.
4. Alsatie M, Chalasani N, Kwo PY. Management of hepatitis C infection after liver transplantation. Drugs 2007; 67:871-885. (Pubitemid 46607388)
5. Berenguer M. Management of hepatitis C virus in the transplant patient. Clin Liver Dis 2007; 11:355-376. (Pubitemid 46994759)
6. Said A, Einstein M, Lucey MR. Liver transplantation: an update 2007. Curr Opin Gastroenterol 2007; 23:292-298.
7. Cisneros L, Londorio MC, Blasco C, et al. Hepatic stellate cell activation in liver transplant patients with hepatitis C recurrence and in nontransplanted patients with chronic hepatitis C. Liver Transpl 2007; 13:1017-1027. (Pubitemid 47163195)
8. Eid AJ, Brown RA, Paya CV, Razonable RR. Association between Toll-like receptor polymorphisms and the outcome of liver transplantation for chronic hepatitis C virus. Transplantation 2007; 84:511-516.
9. Bharat A, Narayanan K, Golocheikine A, et al. Elevated soluble CD30 characterizes patients with hepatitis C virus-induced liver allograft cirrhosis. Transplantation 2007; 84:1704-1707.
10. + innate lymphocyte populations associated with severity of hepatitis C virus recurrence. Liver Transpl 2008; 14:31-40.
11. Saliba F, Lakehal M, Pageaux GP, et al. Risk factors for new-onset diabetes mellitus following liver transplantation and impact of hepatitis C infection: an observational multicenter study. Liver Transpl 2007; 13:136-144. (Pubitemid 46099983)
12. Delgado-Borrrho S, Liu YS, Jordan SH, et al. Prospective study of liver transplant recipients with HCV infection: evidence for a causal relationship between HCV and insulin resistance. Liver Transpl 2008; 14:193-201.
13. Hanouneh IA, Feldstein AE, Mccullough AJ, et al. the significance of metabolic syndrome in the setting of recurrent hepatitis C after liver transplantation. Liver Transpl 2008; 14:1287-1293.
14. D'Errico-Grigioni A, Fiorentino M, Vasuri F, et al. Tissue hepatitis C virus RNA quantification and protein expression help identify early hepatitis C virus recurrence alter liver transplantation. Liver Transpl 2008; 14:313-320.
15. Tretheway D, Jain A, LaPoint R, et al. Should trichrome stain be used on all postliver transplant biopsies with hepatitis C virus infection to estimate the fibrosis score? Liver Transpl 2008; 14:695-700.
16. Pungpapong S, Nunes DP, Krishna M, et al. Serum fibrosis markers can predict rapid fibrosis progression after liver transplantation for hepatitis C. Liver Transpl 2008; 14:1294-1302.
17. Harada N, Soejima Y, Taketomi A, et al. Assessment of grafofibrosis by transient elastography in patients with recurrent hepatitis C after liver transplantation. Transplantation 2008; 85:69-74.
18. Oo YH, Dudley T, Nightingale P, et al. Tacrolimus and cyclosporine doses and blood levels in hepatitis C and alcoholic liver disease patients after liver transplantation. Liver Transpl 2008; 14:81-87. (Pubitemid 351167993)
19. Berenguer M, Royuela A, Zamora J. Immunosuppression with calcineurin inhibitors with respect to the outcome of HCV recurrence after liver transplantation: results of a meta-analysis. Liver Transpl 2007; 13:21-29. (Pubitemid 46099970)
20. Vivarelli M, Burra P, La Barba G, et al. Influence of steroids on HCV recurrence after liver transplantation: a prospective study. J Hepatol 2007; 47:793-798. (Pubitemid 350051119)
21. Kato T, Gaynor JJ, Yoshida H, et al. Randomized trial of steroid-free induction versus corticosteroid maintenance among orthotopic liver transplant recipients with hepatitis C virus: impact on hepatic fibrosis progression at one year. Transplantation 2007; 84:829-835. (Pubitemid 351338942)
22. Klintmalm GBG, Washburn WK, Rudich SM, et al. Corticosteroid-free immunosuppression with daclizumab in HCV+ liver transplant recipients: 1-year interim results of the HCV-3 study. Liver Transpl 2007; 13:1521-1531.
23. Picciotto FP, Tritto G, Lanza AG, et al. Sustained virological response to antiviral therapy reduces mortality in HCV reinfection after liver transplantation. J Hepatol 2007; 46:459-465. (Pubitemid 46185706)
24. Angelico M, Petrolati A, Lionetti R, et al. A randomized study on PEG-interferon alfa-2a with or without ribavirin in liver transplant recipients with recurrent hepatitis C. J Hepatol 2007; 46:1009-1017. (Pubitemid 46680357)
25. Carrion JA, Navasa M, Garcia-Retortillo M, et al. Efficacy of antiviral therapy on hepatitis C recurrence after liver transplantation: a randomized controlled study. Gastroenterology 2007; 132:1746-1756. (Pubitemid 46695723)
26. Kornberg A, Kupper B, Tannapfel A, et al. Sustained clearance of serum hepatitis C virus-RNA independently predicts long-term survival in liver transplant patients with recurrent hepatitis C. Transplantation 2008; 86:469-473.
27. Takada Y, Ito T, Uedo Y, et al. Effects of double-filtration plasmapheresis combined with interferon plus ribavirin for recurrent hepatitis C after living donor liver transplantation. Liver Transpl 2008; 14:1044-1047. (Pubitemid 352003905)
28. Hanouneh IA, Miller C, Aucejo F, et al. Recurrent hepatitis C after liver transplantation: on-treatment prediction of response to peginterferon/ribavirin therapy. Liver Transpl 2008; 14:53-58. (Pubitemid 351167989)
29. Iacob S, Cicinnati VR, Hilgard P, et al. Predictors of graft and patient survival in hepatitis C virus (HCV) recipients: model to predict HCV cirrhosis after liver transplantation. Transplantation 2007; 84:56-63. (Pubitemid 47094642)
30. Berenguer M, Palau A, Aguilera, et al. Clinical benefits of antiviral therapy in patients with recurrent hepatitis C following liver transplantation. Am J Transplant 2008; 8:679-687. (Pubitemid 351287553)
31. Ueda Y, Takada Y, Haga H, et al. Limited benefit of biochemical response to combination therapy for patients with recurrent hepatitis C after living-donor liver transplantation. Transplantation 2008; 85:855-865.
32. Terrault NA, Shiffman ML, Lok ASF, et al. Outcomes in hepatitis C virus-infected recipients of living donor vs. deceased donor liver transplantation. Liver Transpl 2007; 13:122-129. (Pubitemid 46099981)